GeoVax Labs, Inc.
$1.17
▼
-5.67%
2026-04-21 07:09:02
www.geovax.com
NCM: GOVX
Explore GeoVax Labs, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.38 M
Current Price
$1.17
52W High / Low
$34.75 / $1.14
Stock P/E
—
Book Value
$4.13
Dividend Yield
—
ROCE
-498.05%
ROE
-3.77%
Face Value
—
EPS
$-31.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
3.81
Debt / Equity
—
Current Ratio
3.57
Quick Ratio
2.55
Forward P/E
-1.43
Price / Sales
0.82
Enterprise Value
$-3.55 M
EV / EBITDA
0.14
EV / Revenue
-1.06
Rating
Strong Buy
Target Price
$190.83
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 2. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 3. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
| 4. | Longeveron Inc. | $1.04 | — | $25.59 M | — | -377.18% | -1.65% | $1.83 / $0.47 | $0.25 |
| 5. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 6. | Inhibrx Biosciences, Inc. | $82.39 | — | $1.29 B | — | -119.83% | -1.98% | $94.56 / $10.84 | $0.55 |
| 7. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0.85 M | 1.64 M | 0.86 M | 2.79 M |
| Operating Profit | -6.37 M | -5.42 M | -5.41 M | -8.34 M | -5.85 M |
| Net Profit | -6.32 M | -5.37 M | -5.36 M | -8.26 M | -5.82 M |
| EPS in Rs | -2.84 | -2.41 | -2.41 | -3.72 | -2.62 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 3.95 M | 0 M | 0.08 M | 0.39 M |
| Operating Profit | -25.14 M | -26.74 M | -14.03 M | -18.75 M |
| Net Profit | -24.99 M | -25.97 M | -14.02 M | -18.57 M |
| EPS in Rs | -11.24 | -11.68 | -6.31 | -8.35 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 8.16 M | 9.28 M | 31.35 M | 11.8 M |
| Total Liabilities | 3.11 M | 3.52 M | 4.75 M | 7.44 M |
| Equity | 5.05 M | 5.76 M | 26.6 M | 4.36 M |
| Current Assets | 7.93 M | 7.89 M | 28.94 M | 11.63 M |
| Current Liabilities | 3.11 M | 3.52 M | 4.75 M | 5.44 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -24.68 M | -25.17 M | -19.03 M | -11.2 M |
| Investing CF | -0.02 M | -0.05 M | -0.13 M | -0.05 M |
| Financing CF | 23.75 M | 4.06 M | 35.35 M | 12.78 M |
| Free CF | -24.7 M | -25.22 M | -19.16 M | -11.24 M |
| Capex | -0.02 M | -0.05 M | -0.13 M | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | -78.85% | — |
| Earnings Growth % | 3.75% | -85.2% | 24.5% | — |
| Profit Margin % | -631.98% | — | -17198.35% | -4817.19% |
| Operating Margin % | -635.83% | — | -17207.47% | -4862.72% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -629.03% | — | -17138.43% | -4806.86% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-12 | 1:0.04 |
| 2024-01-31 | 1:0.0666667 |